Consumers and doctors agree that pharma ads help patients: But marketers must still create ad campaigns that better represent patients’ real-life experiences.
Havas Lynx’s global healthcare influencer offering reflects channel shift: Marketers increasingly devote resources to digital channels that physicians are engaging with, like social media.
Retail pharmacies’ plight is Amazon’s gain: The online pharmacy is doubling down on fast medication delivery to capture market share from pharmacy incumbents.
WeightWatchers is the latest company to offer compounded GLP-1s: Consumer demand for cheaper versions of GLP-1s is forcing even weight-loss industry legacy players to sell the meds.
Employers don’t know how their Rx drug benefits are managed: They’re nearing their wits’ end with pharmacy benefit managers and the legal liabilities that arise from the mismanagement of prescription drug benefits.
Biogen, Talkiatry offer services to patients with postpartum depression: We examine whether drugmaker-telehealth tie-ups are what’s best for patients.
Activist investor takes $1B stake in Pfizer, eyes a performance turnaround: But to the drugmaker’s credit, its plan to diversify the therapeutic areas it will focus on moving forward should place it in line with investors’ expectations.
Patient care is being disrupted by cyberattacks: Cyberattacks aren’t just causing financial disruptions—they’re causing real patient harm, too.
The Epic, Particle Health saga unpacked: Particle’s recent filing of an antitrust lawsuit raises salient points on patient data privacy and anti-competitive behavior in healthcare.
CA governor signs two healthcare AI bills into law: Lawmakers believe AI should be used as a supplementary tool when it comes to patient care.
More bad news for Medicare Advantage insurers: Humana’s huge drop in star ratings is another indicator that MA plans will likely cut seniors’ benefits in the future.
Blue Shield of California negotiates for cheaper version of biosimilar: This is the first time a health insurer has used this approach to bring a Humira biosimilar to market, circumventing pharmacy benefit managers entirely.
Eli Lilly’s GLP-1 medication shortage ends: The host of players who offer compounded versions of the blockbuster drugs don’t have to worry—yet.
Consumers’ telehealth satisfaction varies from visit to visit: We explore the competitive telehealth market and examine how virtual care players are adapting to remain viable.
US voters want presidential candidates to address high healthcare costs: We think each campaign will make this a priority over the next month.
Ad spending projects to hold strong in healthcare and pharma: Here’s why health and pharma marketers are prioritizing some media channels over others.
CVS Health explores possible company breakup: A series of concurrent headwinds are impacting multiple sectors of CVS Health’s business, leading concerned investors to step in and try to force its hand.
A focus on longer battery life and lighter design could secure a lead over Samsung in the high-growth wearables market.
TikTok, World Health Organization join forces to combat medical misinformation: After being scrutinized for the impact that misinformation on its platform has had on younger users, TikTok is taking a page out of YouTube’s book to fight it.
Docs deem AI Overviews a risky source of medical information: AI-generated summaries of users’ health searches are imperfect. They’ll need to get better given consumers' many options to obtain health info.